Study Type
Intervention - Procedure
Given the current rates of amputation and death in chronic limb threatning ischemia, improving outcomes after infrainguinal percutaneous revascularization would have a tremendous public health impact. Translating emerging intravascular imaging evidence from coronary disease to high-risk peripheral arterial disease patients should be prioritized.
Therefore, the aim of the CLARITY Vanguard Phase is determine the feasibility of conducting a large, multicenter randomized controlled trial to examine whether an intravascular ultrasound (IVUS)-guided strategy is effective and safe to prevent major adverse limb events (MALE), defined as above-ankle amputation or clinically driven target lesion revascularization, or target lesion binary restenosis, defined as > 50% stenosis, in patients with chronic limb-threatening ischemia undergoing percutaneous revascularization.
Intervention - Procedure
Randomized controlled trial
2
5
100 (vanguard)
2025-2027
PHRI
The CLARITY study team at Hamilton General Hospital, including principal investigators Marc-André d’Entremont and Sanjit Jolly, after enrolling the first patient on December 19, 2025.
Back To Top